Physician profile
Thomas E Palmer
NPI 1811992373
$1,359.26
in general payments reported to CMS, 2019-2025
16 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $26.88 · 2021: $35.37 · 2022: $62.65 · 2023: $403 · 2024: $100 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $316.67 | 2019-2025 | Erleada, Stelara |
| Coloplast Corp | $206.45 | 2023-2024 | Titan |
| Medtronic, INC. | $116.66 | 2021-2023 | Interstim |
| Boston Scientific Corporation | $107.18 | 2025 | General - Hemostasis |
| Pfizer INC. | $104.14 | 2019-2025 | |
| Cook Medical LLC | $93.13 | 2023 | Fiber Dust |
| Astellas Pharma US INC | $67.86 | 2019-2022 | |
| Abbvie INC. | $64.73 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $61.51 | 2019 | |
| Dendreon Pharmaceuticals LLC | $59.73 | 2019-2024 | Provenge |
| Edap Technomed INC | $50.00 | 2023 | |
| Allergan, INC. | $48.95 | 2019 | |
| Genzyme Corporation | $25.69 | 2022 | |
| Travere Therapeutics, INC. | $20.31 | 2019 | |
| Endo Pharmaceuticals INC. | $16.25 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.